---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-134501"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:13:18.255620+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioAtla initiates strategic review to monetize assets; Q4 net loss $9.8M, cash $7.1M

## Summary
- Board launched formal process to explore sale, licensing, or other strategic options; Tungsten Advisors engaged.
- Net loss Q4 2025: $9.8M versus $14.9M year ago; full year net loss $59.6M.
- Cash and equivalents $7.1M at Dec 31, 2025; company expects to extend runway via cost cuts and equity facility.
- March 2026 workforce reduction implemented; re-evaluating Phase 1 BA3182 enrollment and Phase 3 ozuriftamab vedotin timeline.
- Pre-paid advance agreements fully converted to common stock; no remaining obligations.

## SEC filing metadata
- accession: 0001193125-26-134501
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000119312526134501/0001193125-26-134501-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000119312526134501/bcab-20260331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-134501
- JSON: https://secwatch.observer/filing/0001193125-26-134501.json
- Plain text: https://secwatch.observer/filing/0001193125-26-134501.txt

## Key facts
- Earnings Releases
  BioAtla, Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue Collaboration and other revenue was $2.0 million for the fourth quarter and full year 2025, net income Net loss for the fourth quarter of 2025 was $9.8 million, compared to a net loss of $14.9 million for the same period in.
  - Period: fourth quarter and full year ended December 31, 2025
  - Revenue: Collaboration and other revenue was $2.0 million for the fourth quarter and full year 2025
  - Net income: Net loss for the fourth quarter of 2025 was $9.8 million, compared to a net loss of $14.9 million for the same period in
  - Result: reported results
  source text: BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and business Highlights – Initiated a formal process to monetize assets – Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 – BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the full year and fourth quarter ended December 31, 2025 and provided business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826892/000119312526134501/0001193125-26-134501-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.